Covidien adds new tech to patient monitoring business
This article was originally published in Clinica
Executive Summary
Covidien is set to enhance its patient monitoring technology with advanced signal processing techniques acquired from CardioDigital. The acquired technology assets will be used by Covidien's respiratory and monitoring solutions business unit and integrated into the Nellocor pulse oximetry platform. Terms of the transaction were not disclosed. In a separate announcement, Covidien reported that its third-quarter fiscal 2008 sales went up 14% to $2.6bn, driving by double-digit growth in it medical devices, imaging solutions and pharmaceutical products business segments. Net income improved to $269m, compared to a loss of $1.1bn recorded in the same quarter in fiscal 2008.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.